The weight of the decision, the relentless pressure, proved too much. Dr. Vinay Prasad, a key figure at the Food and Drug Administration, initially stepped away from his pivotal roles – Chief Medical Officer, Chief Scientific Officer, and Director of the Center for Biologics Evaluation and Research.
That departure, however, was remarkably brief. Within two weeks, bolstered by unwavering support from FDA leadership and prominent health officials, Prasad returned to the agency, resuming his oversight of vaccines and cutting-edge biologic treatments. It seemed a temporary crisis had passed.
Now, Prasad is leaving again, this time after a prolonged period of intensifying conflict. Months of escalating disputes with powerful biotech companies and pharmaceutical manufacturers have culminated in his second exit, signaling a deeper, more complex struggle within the agency.
The announcement came late on a Friday, delivered by FDA Commissioner Marty Makary to staff. Prasad will return to his academic position at the University of California, San Francisco, at the end of April, leaving behind a trail of controversy and challenging decisions.
The recent friction began with a surprising rejection. Prasad initially refused to allow the FDA to review Moderna’s highly anticipated mRNA flu vaccine – an unusual move that prompted the drugmaker to publicly challenge the decision and vow a formal appeal.
The FDA swiftly reversed course, agreeing to review the vaccine, but only after Moderna committed to providing additional study data. This initial clash exposed a growing tension between the agency and a major pharmaceutical player.
The situation escalated further with a public dispute involving UniQure, a smaller company developing a potentially life-altering treatment for Huntington’s Disease, a devastating condition affecting roughly 40,000 Americans.
The FDA unexpectedly demanded a new clinical trial for UniQure’s gene therapy, one that would require performing sham surgery on some patients. This request, involving a placebo surgery directly into the brain, sparked outrage and ethical concerns from the company’s executives.
UniQure argued that the FDA’s demand contradicted established agency guidance and presented unacceptable risks to patients. The request for a sham-controlled trial, in a procedure as invasive as gene therapy, ignited a fierce debate about the agency’s direction and priorities.
